These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 30216722

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
    Cho H, Lee E, Kwon HA, Seul L, Jeon HJ, Yu JH, Ryu JH, Jeon R.
    Int J Mol Sci; 2020 Oct 25; 21(21):. PubMed ID: 33113810
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
    Yao X, Sun X, Jin S, Yang L, Xu H, Rao Y.
    J Med Chem; 2019 Jul 25; 62(14):6561-6574. PubMed ID: 31260299
    [Abstract] [Full Text] [Related]

  • 7. Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
    Kawahata W, Asami T, Kiyoi T, Irie T, Kashimoto S, Furuichi H, Sawa M.
    J Med Chem; 2021 Oct 14; 64(19):14129-14141. PubMed ID: 34529443
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L, Pei H, Zhang C, Shao M, Li D, Tang M, Wang T, Chen X, Xiang M, Chen L.
    Eur J Med Chem; 2018 Feb 10; 145():96-112. PubMed ID: 29324347
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.
    Huang W, Wang S, Zhang Z, Zhang C, Zeng S, Liang M, Shen Z, Liu X.
    Bioorg Chem; 2020 Dec 10; 105():104377. PubMed ID: 33091668
    [Abstract] [Full Text] [Related]

  • 19. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
    Qiu H, Liu-Bujalski L, Caldwell RD, Follis AV, Gardberg A, Goutopoulos A, Grenningloh R, Head J, Johnson T, Jones R, Mochalkin I, Morandi F, Neagu C, Sherer B.
    Bioorg Med Chem Lett; 2018 Sep 15; 28(17):2939-2944. PubMed ID: 30122225
    [Abstract] [Full Text] [Related]

  • 20. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F, Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z.
    J Med Chem; 2019 Sep 12; 62(17):7923-7940. PubMed ID: 31381333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.